Houlihan Lokey Advises Revelstoke Capital Partners on its Minority Equity GP Stake Sale

Houlihan Lokey is pleased to announce that Revelstoke Capital Partners (Revelstoke) has received a strategic minority investment from Bonaccord Capital Partners (Bonaccord).

The transaction further solidifies Houlihan Lokey’s dominance in GP advisory transactions, with eight executed transactions in 2023.

Revelstoke, a healthcare-focused private equity firm with $5.6 billion of assets under management, announced that Bonaccord made a passive minority investment in the firm.

Bonaccord’s investment provides Revelstoke with long-term capital to pursue strategic investments and growth initiatives. There will be no change to Revelstoke’s investment process, day-to-day management, or firm operations.

Revelstoke has experienced significant growth since its founding in 2013, having raised three flagship private equity funds, three single-asset continuation vehicles under the EPIC series, and numerous co-investment vehicles. Across these investment vehicles, Revelstoke has completed 184 acquisitions, which include 26 platform companies and 158 add-on acquisitions.

Founded in 2017 and based out of New York, Bonaccord is a private equity firm focused on acquiring noncontrol equity interests in middle-market private markets sponsors spanning private equity, private credit, real estate, and real assets. By leveraging its strategic relationships, institutional capabilities, and strategic development expertise, Bonaccord seeks to support transformative initiatives that help its portfolio companies reach their potential and establish enduring institutions.

Houlihan Lokey served as a financial advisor to Revelstoke.

This transaction represents an additional successful engagement for Houlihan Lokey’s market-leading GP advisory platform.

RELATED: Financial Sponsors Coverage, Healthcare, Private Funds Advisory